{"organizations": [], "uuid": "756eee00af650c54b86870d7e45062fb92c8fad2", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-kala-pharmaceuticals-announces-nda/brief-kala-pharmaceuticals-announces-nda-for-inveltystm-accepted-by-u-s-fda-idUSASB0BZVB", "country": "US", "domain_rank": 408, "title": "BRIEF-Kala Pharmaceuticals Announces NDA For Inveltystm Accepted By U.S. FDA", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-05T14:09:00.000+02:00", "replies_count": 0, "uuid": "756eee00af650c54b86870d7e45062fb92c8fad2"}, "author": "", "url": "https://www.reuters.com/article/brief-kala-pharmaceuticals-announces-nda/brief-kala-pharmaceuticals-announces-nda-for-inveltystm-accepted-by-u-s-fda-idUSASB0BZVB", "ord_in_thread": 0, "title": "BRIEF-Kala Pharmaceuticals Announces NDA For Inveltystm Accepted By U.S. FDA", "locations": [], "entities": {"persons": [], "locations": [{"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "brief-kala pharmaceuticals announces nda", "sentiment": "negative"}, {"name": "fda", "sentiment": "none"}, {"name": "reuters staff", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "reuters) - kala pharmaceuticals inc", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": " 10 PM / in 11 minutes BRIEF-Kala Pharmaceuticals Announces NDA For Inveltystm Accepted By U.S. FDA Reuters Staff 1 Min Read \nJan 5 (Reuters) - Kala Pharmaceuticals Inc: \n* KALA PHARMACEUTICALS ANNOUNCES NEW DRUG APPLICATION FOR INVELTYSTM (KPI-121 1%) HAS BEEN ACCEPTED FOR REVIEW BY THE U.S. FOOD AND DRUG ADMINISTRATION \n* KALA PHARMACEUTICALS INC - BRAND NAME FOR KPI-121 1%, INVELTYS, HAS BEEN CONDITIONALLY APPROVED BY FDA \n* KALA PHARMA-FDA INDICATES APPLICATION FOR INVELTYSTM SUFFICIENTLY COMPLETE TO PERMIT SUBSTANTIVE REVIEW,SET PDUFA TARGET ACTION DATE OF AUGUST 24,2018â€‹ Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-01-05T14:09:00.000+02:00", "crawled": "2018-01-05T14:32:47.000+02:00", "highlightTitle": ""}